Page 2432 - Williams Hematology ( PDFDrive )

2403
2402 Index Index 2403

Ataxia-telangiectasia-like disorder, 1227 in lymphomas, 187 classification, 824, 824t
Ataxia-telangiectasia mutated and in mantle cell lymphoma, 187, 236t, 1654 clinical features, 831–832
rad3-related (ATR) kinase, 532 Atovaquone course and prognosis, 840
Atazanavir, 1249 for babesiosis, 819 epidemiology, 825, 827
ATG. See Antithymocyte globulin (ATG) as empiric therapy for infections, 386 etiology, 828
Atheroembolism, 2101, 2102f, 2298 prophylactic, 389 laboratory features, 832–833, 833f, 834t
Atheromatous embolism, 2298 ATP (adenosine triphosphate) pathogenesis, 829, 2348
Atherosclerosis, 2281–2291 in glucose metabolism, 192, 692 serologic features, 835–836
in antiphospholipid syndrome, 2237, in platelet metabolism, 1839–1840 therapy, 839
2237f, 2240 receptors for, 1874 course and prognosis, 840
carotid artery, 2297 ATP-dependent chromatin remodeling definition and history, 823–824
endothelial dysfunction in, 2282–2285 complexes (remodelers), 166–168, differential diagnosis, 836–837
blood fluidity and, 2285 166f direct antiglobulin test findings in, 823,
inflammation, 2282f ATP diphosphohydrolase. See CD39 833, 834t
progenitor cells and, 2285 ATRA (all-trans-retinoic acid), 335 drug-induced. See Hemolytic anemia,
vascular growth and, 2283–2285, 2284f for acute myelogenous leukemia, 1396, drug-induced immune
vascular tone and, 2282–2283, 2282f 1404, 1409 laboratory features, 832–834, 833f
inflammation and, 2285–2288 for acute promyelocytic leukemia, 1391, primary/idiopathic, 824, 827
adaptive immunity, 2286 1404–1406, 1405t secondary, 824, 827
adhesion molecules, 2286 in pregnancy, 124 therapy, 837
CD40 and CD40 ligand, 2288 dose and action mechanism, 1404–1405 warm-antibody
genetics, 2288 for Langerhans cell histiocytosis, 1107 classification, 824, 824t
high-density lipoprotein levels, resistance to, 197 clinical features, 832
2287–2288 toxic effects, 1405 course and prognosis, 840
immune cells, 2286 ATRX, 1346t, 1353 epidemiology, 825
infection, 2288 Atypical chronic myelogenous leukemia etiology, 827–828
innate immunity, 2285–2286 (aCML), 1279, 1473 laboratory features, 832–834, 833f,
lipid peroxidation, 2287 Atypical hemolytic uremic syndrome 834t
lipoprotein phospholipase A , 2286 (aHUS), 1932, 1953, 2259–2261, pathogenesis, 828–829, 2348
2
low-density lipoprotein in vascular wall, 2259t serologic features, 834–835, 834f
2287 Atypical myeloproliferative disease, 1473 therapy, 838–839
scavenger receptors, 2287 Auer rods, 23, 1390 thrombocytopenia with. See Evans
splenectomy, 2288 Aurora kinase inhibitors, 1403 syndrome
transforming growth factor-β, 2288 Autoantibodies Autoimmune lymphoproliferative syndrome
monocytes/macrophages in, 1079 development, 2183–2184 (ALPS), 210, 1224, 1575t
plaque in induction, 825f, 830t, 831 Autoimmune neutropenia, 995, 996f, 2358
atherothrombi formation and. See red cell, 2343. See also Erythrocyte Autoimmune polyendocrinopathy-
Arterial thrombosis antibodies candidiasis ectodermal dystrophy
classification, 2288–2289, 2289f Autoimmune diseases (APECED), 87, 1181, 1224
formation, 1975f antiphospholipid syndrome and, 2238 Autoimmune thrombocytopenic purpura. See
life span, 2282f aplastic anemia and, 518 Immune thrombocytopenia (ITP)
vulnerable, 2289–2291, 2290f, cobalamin deficiency and, 600 Autoimmunity
2291t hyposplenism and, 868 forward feedback loops and, 304
risk factors, 2281–2282, 2282t lymphocytopenia and, 1206 lymphomas and, 1574–1575
Atherothrombosis myeloma and, 1734 Autologous blood donations, 2367–2368
arterial thrombosis and. See Arterial primary immunodeficiency Autologous hematopoietic stem cell
thrombosis disorders presenting as. See transplantation. See Hematopoietic
definition, 2291 Immunodeficiency diseases, cell transplantation (HCT),
gene variants, 1850, 1850f primary, presenting as autoimmune autologous
ATL/ATLL. See Adult T-cell leukemia/ diseases Autologous stem cell infusion
lymphoma (ATL/ATLL) thrombotic microangiopathy and, 2262 for acute myelogenous leukemia, 1399,
ATM Autoimmune hemolytic anemia, 823–840 1408
in acute lymphoblastic leukemia, 1507 in chronic lymphocytic leukemia, 824, 827, for chronic myelogenous leukemia, 1460
in ataxia-telangiectasia, 1227 831, 839, 840, 1541 for myelodysplastic syndromes, 1362
in chronic lymphocytic leukemia, 187, classification, 824–825, 824t Autophagy, 487, 1062, 1065f
231t, 1529 cold-antibody Autosomal dominant inheritance, 148, 148f

Kaushansky_index_p2393-2506.indd 2403 9/21/15 3:21 PM